WO2001013899A2 - Wirkstoffhaltiges therapeutisches system mit mindestens zwei polymerhaltigen schichten - Google Patents

Wirkstoffhaltiges therapeutisches system mit mindestens zwei polymerhaltigen schichten Download PDF

Info

Publication number
WO2001013899A2
WO2001013899A2 PCT/EP2000/007900 EP0007900W WO0113899A2 WO 2001013899 A2 WO2001013899 A2 WO 2001013899A2 EP 0007900 W EP0007900 W EP 0007900W WO 0113899 A2 WO0113899 A2 WO 0113899A2
Authority
WO
WIPO (PCT)
Prior art keywords
layers
therapeutic system
polymer
active substance
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/007900
Other languages
German (de)
English (en)
French (fr)
Other versions
WO2001013899A3 (de
Inventor
Achim Berthold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Priority to DE50015307T priority Critical patent/DE50015307D1/de
Priority to JP2001518037A priority patent/JP2003507417A/ja
Priority to EP00958444A priority patent/EP1143939B1/de
Priority to AU69957/00A priority patent/AU6995700A/en
Priority to US09/830,300 priority patent/US7279178B1/en
Publication of WO2001013899A2 publication Critical patent/WO2001013899A2/de
Publication of WO2001013899A3 publication Critical patent/WO2001013899A3/de
Anticipated expiration legal-status Critical
Priority to US10/991,713 priority patent/US7335378B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B27/00—Layered products comprising a layer of synthetic resin
    • B32B27/06—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material
    • B32B27/08—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B27/00—Layered products comprising a layer of synthetic resin
    • B32B27/18—Layered products comprising a layer of synthetic resin characterised by the use of special additives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B7/00—Layered products characterised by the relation between layers; Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical properties; Layered products characterised by the interconnection of layers
    • B32B7/02—Physical, chemical or physicochemical properties
    • B32B7/027—Thermal properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B7/00—Layered products characterised by the relation between layers; Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical properties; Layered products characterised by the interconnection of layers
    • B32B7/04—Interconnection of layers
    • B32B7/06—Interconnection of layers permitting easy separation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A61L2300/608—Coatings having two or more layers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2250/00—Layers arrangement
    • B32B2250/05—5 or more layers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2535/00—Medical equipment, e.g. bandage, prostheses or catheter
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B2556/00—Patches, e.g. medical patches, repair patches

Definitions

  • Therapeutic system containing active ingredients for application to the skin with at least two polymer-containing layers
  • the invention relates to an active substance-containing therapeutic system for application to the skin with at least two polymer-containing layers.
  • the invention further relates to a production method and a use of the therapeutic system.
  • the pharmaceutical preparation for delivering active ingredients to the skin is aimed either at a transdermal systemic action or a dermal, local action of the released active ingredients.
  • Adhesion to the application area is ensured by adhesives which form highly viscous, permanently adhesive structures.
  • quality features such as initial tack (tack), adhesive power (adhesion) and the internal strength of the pressure sensitive adhesive (cohesion).
  • the pharmaceutical preparation is an active substance-containing device that releases one or more drugs at a predeterminable rate continuously over a specified period of time at a specified location.
  • a dosage program referred to as a dosage program
  • TS therapeutic system
  • systems according to the invention are applied to the skin as plasters in order to achieve either a systemic or a local effect, one speaks in this connection of transdermal therapeutic systems (TTS) or of dermal therapeutic systems (DTS).
  • TTS transdermal therapeutic systems
  • DTS dermal therapeutic systems
  • the preparation according to the invention has a high efficiency. This means that the preparation leads to a high bioavailability of active ingredients. The effect can be stopped at any time by simply removing the preparation.
  • the preparation is also characterized by the controllability of the active ingredient deliveries.
  • the preparation according to the invention also has a high degree of reliability with regard to the patient's compliance with the therapy plan (patient acceptance, so-called compliance), since the frequency of application is greatly reduced in comparison to conventional pharmaceutical forms and side effects rarely occur. Furthermore, the amount of active substance that can be applied can generally be reduced. In this way, dose-dependent side effects are also reduced or avoided. This results in increased therapy safety.
  • an active substance-containing system comprises a structure with several layers, comprising at least one reservoir layer containing active substances and / or auxiliary substances, a backing layer impermeable for its ingredients and a protective layer to be removed from the skin before application.
  • the reservoir layer generally consists of an amorphous polymer containing an active ingredient and / or auxiliary.
  • amorphous polymers tend to tend to be comparatively inadequate cohesion, especially after prolonged storage in the pavement to cold river.
  • the molecular movement increases with increasing temperature in several, mostly 5 different, reversible stages.
  • the transition from the glass state to the rubber-like state is accompanied by a significant change in the physical properties such as specific volume, elastic modulus, heat capacity, thermomechanical properties and refractive index.
  • the melting point ( ⁇ n; solid and liquid polymer in equilibrium) of amorphous polymers is defined by partially crystalline polymer areas.
  • Tg is always lower than Tm.
  • Cold flow describes a material property.
  • the materials concerned begin to flow during storage without being exposed to special influences and can therefore be regarded as highly viscous liquids.
  • TTS and DTS often tend to cold flow. This means that a plaster sticks to the primary packaging during storage and can then only be removed with difficulty.
  • plasters with a cold flow leave black edges, adhesive residues, on the application surface after their application, some of which can only be removed with intensive cleaning measures.
  • WO 86/00814 and US Pat. No. 5,186,938 describe the possibility of improving the cold flow of glycerol trinitrate-containing, self-adhesive polymers derived from polyacrylic acid by crosslinking the polymers.
  • divalent metal ions or melamine are used for crosslinking. This creates a coherent network that tends to flow much less coldly than the starting polymer. Networking that has a positive effect on cohesion has a negative influence on stickiness, which deteriorates as a result. The latter is a general rule of thumb.
  • the inventors of the known method try to solve the problem by using the agent which effects the crosslinking only in a relatively small amount in order to ensure a minimum stickiness.
  • the problem with the described procedure is that the degree of cross-linking must be set exactly in order to ensure optimal system properties.
  • the invention has for its object to provide a method for improving cohesion for the purpose of significantly reducing the cold flow, which at least largely overcomes the difficulties and technical limits observed so far and leads to a high bioavailability of the active ingredients and auxiliaries contained ,
  • the object is achieved according to claim 1 by a layered structure of the TTS or DTS.
  • the different layers differ in their glass transition temperature (Tg).
  • Tg glass transition temperature
  • the layer (s) with the higher glass transition temperature (s) leads to an improvement in the cohesion of the entire system.
  • the cold flow is reduced, so that the problem that the TTS or DTS stick to the primary packaging during storage and, after their application, leave black edges due to adhesive residues on the application surface no longer occurs or is greatly reduced.
  • incompatibilities are avoided by the fact that the polymers used are present in different layers and so their interaction remains essentially restricted to the interfaces. In In favorable cases, cross-linking can be dispensed with.
  • One of the layers can also be designed as a control means for the active ingredient release.
  • the method according to the invention provides that at least one of the layers is designed and arranged as an active substance reservoir.
  • a method for producing the therapeutic system comprises the steps of laminating at least two polymer-containing layers on one another, the layers containing polymers which differ in their glass transition temperature.
  • a use of the therapeutic system according to the invention serves for the topical or transdermal delivery of active substances to the skin of an organism.
  • FIG. 1 An exemplary, schematic representation of the system according to the invention can be seen in FIG. 1.
  • An exemplary embodiment is shown therein, which consists of five layers (a to e).
  • the layers are: a) backing layer b) matrix la with a polymer labeled Tgl, c) matrix 2 with a polymer labeled Tg2, d) matrix lb with a polymer labeled Tgl, e) protective layer, where Tg2> Tgl is.
  • Durotak ® 387-2287 were successively 38.84 g of an adhesive solution, 11.50 g of a tackiness imparting resin (Hercolyn D) 7.5 g of glycerol and 6.0 g of a solution of aluminum acetylacetonate in ethyl acetate (4 parts by weight) were added and subsequently homogenized. The resulting mass had a solids content of 45% by weight.
  • This composition was then applied to a siliconized polyester foil (Hostaphan ® RN100) by means of film applicator in a film thickness of 250 microns and dried under defined conditions (30 min at 50 ° C). The dried film was covered with a flexible polyester film (Hostaphan "RN15), which represented the later backing layer.
  • the matrix lb was produced in an analogous manner, with the difference that the final covering was exposed with a flexible polyester film.
  • the matrix 2 was prepared first dissolved 30.0 g of a high molecular weight polymer based on methacrylic acid ester (Plastoid ® B) in ethyl acetate, so that a 30% by weight solution resulted. This solution was applied to a siliconized polyester film (Hostaphan "RN100) using a film puller in a Layer thickness of 250 ⁇ m applied and dried under defined conditions (30 min at 50 ° C).
  • the siliconized polyester film was removed from the matrix la and laminated onto the matrix 2.
  • the siliconized polyester film was then removed from the matrix 2 and laminated with the matrix 1b.
  • the result was a system comprising the layers: a) backing layer (Hostaphan ® RN15), b) matrix la, c) matrix 2, d) matrix lb and e) protective film (Hostapphhaann ®® RRNN: 100).
  • the system is shown schematically in FIG. 1.
  • the formulation mentioned and a formulation which contained only the matrices la and lb were stored under defined conditions (40 ° C., 75% relative humidity).
  • the laminate without Matrix 2 showed strong cold flow after only one month. In contrast, such was not observed in the laminate with matrix 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/EP2000/007900 1999-08-25 2000-08-14 Wirkstoffhaltiges therapeutisches system mit mindestens zwei polymerhaltigen schichten Ceased WO2001013899A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE50015307T DE50015307D1 (de) 1999-08-25 2000-08-14 Ag auf die haut mit drei polymerhaltigen schichten
JP2001518037A JP2003507417A (ja) 1999-08-25 2000-08-14 少なくとも二つのポリマー含有層を含む、皮膚に塗布するための活性物質含有治療システム
EP00958444A EP1143939B1 (de) 1999-08-25 2000-08-14 Wirkstoffhaltiges therapeutisches system zum auftrag auf die haut mit drei polymerhaltigen schichten
AU69957/00A AU6995700A (en) 1999-08-25 2000-08-14 Therapeutic system containing an active substance for the application on the skin which contains at least two polymerous layers
US09/830,300 US7279178B1 (en) 1999-08-25 2000-08-14 Therapeutic system containing an active substance for the application on the skin which contains at least two polymerous layers
US10/991,713 US7335378B2 (en) 1999-08-25 2004-11-18 Therapeutic system containing an active substance for the application on the skin which contains at least two polymerous layers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19940238.8 1999-08-25
DE19940238A DE19940238A1 (de) 1999-08-25 1999-08-25 Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/830,300 A-371-Of-International US7279178B1 (en) 1999-08-25 2000-08-14 Therapeutic system containing an active substance for the application on the skin which contains at least two polymerous layers
US10/991,713 Division US7335378B2 (en) 1999-08-25 2004-11-18 Therapeutic system containing an active substance for the application on the skin which contains at least two polymerous layers

Publications (2)

Publication Number Publication Date
WO2001013899A2 true WO2001013899A2 (de) 2001-03-01
WO2001013899A3 WO2001013899A3 (de) 2001-08-30

Family

ID=7919502

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/007900 Ceased WO2001013899A2 (de) 1999-08-25 2000-08-14 Wirkstoffhaltiges therapeutisches system mit mindestens zwei polymerhaltigen schichten

Country Status (10)

Country Link
US (2) US7279178B1 (https=)
EP (1) EP1143939B1 (https=)
JP (1) JP2003507417A (https=)
KR (1) KR100701212B1 (https=)
AR (1) AR025390A1 (https=)
AT (1) ATE404182T1 (https=)
AU (1) AU6995700A (https=)
DE (2) DE19940238A1 (https=)
ES (1) ES2312361T3 (https=)
WO (1) WO2001013899A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1737406A2 (en) 2004-03-09 2007-01-03 Mylan Technologies, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US9198877B2 (en) 2004-03-09 2015-12-01 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
PT1256339E (pt) * 2001-05-08 2004-02-27 Lohmann Therapie Syst Lts Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
EP1256340B1 (en) * 2001-05-08 2003-08-13 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
ATE295726T1 (de) * 2002-12-02 2005-06-15 Sanol Arznei Schwarz Gmbh Verabreichung von rotigotine zur behandlung der parkinson'schen krankheit durch iontophorese
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
WO2006082728A1 (ja) * 2005-02-04 2006-08-10 Hisamitsu Pharmaceutical Co., Inc. 経皮吸収貼付剤
DE102006026060B4 (de) * 2006-01-12 2013-01-31 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System enthaltend als Wirkstoff Nikotin und Verfahren zur Herstellung solcher Systeme
JP5190358B2 (ja) * 2006-02-28 2013-04-24 久光製薬株式会社 経皮吸収型製剤
EP3067050A1 (en) 2015-03-13 2016-09-14 Acino AG Transdermal therapeutic system with an overtape comprising two adhesive layers
EA202192644A1 (ru) * 2019-03-28 2021-12-14 Пк Мед Многокомпонентный термопластичный продукт

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57116011A (en) * 1981-01-08 1982-07-19 Nitto Electric Ind Co Ltd Pharmaceutical preparation
JPS6059209B2 (ja) * 1981-08-27 1985-12-24 日東電工株式会社 複合製剤
GB2105990B (en) * 1981-08-27 1985-06-19 Nitto Electric Ind Co Adhesive skin patches
JPS6059208B2 (ja) * 1981-08-27 1985-12-24 日東電工株式会社 複合製剤
DE3347277A1 (de) * 1983-12-28 1985-07-11 Bayer Ag, 5090 Leverkusen Wirkstoffabgabesysteme
JPS61502760A (ja) 1984-07-24 1986-11-27 キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド 粘着性経皮投与層
DE3525767A1 (de) 1985-07-19 1987-01-22 Boehringer Ingelheim Kg Pharmazeutische zubereitung mit kontrollierter und verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
JPS6229003A (ja) * 1985-07-30 1987-02-07 株式会社トキメック 背面反射式光拡散装置
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
JPH0818975B2 (ja) * 1987-06-08 1996-02-28 日東電工株式会社 疾患治療用貼付剤
JP2688062B2 (ja) * 1988-06-20 1997-12-08 積水化学工業株式会社 医療用貼付部材
JP2690112B2 (ja) * 1988-09-14 1997-12-10 積水化学工業株式会社 医療用貼付剤
DE4020144A1 (de) * 1990-06-25 1992-01-09 Lohmann Therapie Syst Lts Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen
JPH04234317A (ja) * 1990-12-28 1992-08-24 Sekisui Chem Co Ltd 貼付剤の製造方法
US5580573A (en) * 1991-02-01 1996-12-03 E. R. Squibb And Sons, Inc. Temperature activated controlled release
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
CA2200060A1 (en) * 1994-09-16 1996-03-21 Jesse C. Ercillo Multi-layer pressure-sensitive adhesive construction
WO1996022084A2 (en) * 1995-01-19 1996-07-25 Cygnus, Inc. Polymer adhesive formulation containing sorbent particles
US6063838A (en) * 1995-02-16 2000-05-16 3M Innovative Properties Company Blended pressure-sensitive adhesives
ES2127711T1 (es) 1996-12-10 1999-05-01 Rotta Res Bv Sistema de administracion transdermal de farmacos para el tratamiento de enfermedades del corazon.
DE19706824C1 (de) * 1997-02-21 1998-03-26 Lohmann Therapie Syst Lts Transdermales oder topisches Plastersystem mit Polyacrylatmatrix mit verbesserten physikalischen Eigenschaften
DE19804604A1 (de) * 1998-02-06 1999-08-12 Beiersdorf Ag Vorrichtung zur Freigabe von Stoffen

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1737406A2 (en) 2004-03-09 2007-01-03 Mylan Technologies, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US9198877B2 (en) 2004-03-09 2015-12-01 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US9492401B2 (en) 2004-03-09 2016-11-15 Mylan Technologies, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery

Also Published As

Publication number Publication date
KR20010080321A (ko) 2001-08-22
EP1143939B1 (de) 2008-08-13
WO2001013899A3 (de) 2001-08-30
DE19940238A1 (de) 2001-03-01
JP2003507417A (ja) 2003-02-25
EP1143939A2 (de) 2001-10-17
US20050136101A1 (en) 2005-06-23
DE50015307D1 (de) 2008-09-25
AR025390A1 (es) 2002-11-27
ATE404182T1 (de) 2008-08-15
AU6995700A (en) 2001-03-19
KR100701212B1 (ko) 2007-03-29
ES2312361T3 (es) 2009-03-01
US7279178B1 (en) 2007-10-09
US7335378B2 (en) 2008-02-26

Similar Documents

Publication Publication Date Title
EP1143939B1 (de) Wirkstoffhaltiges therapeutisches system zum auftrag auf die haut mit drei polymerhaltigen schichten
EP0186019B1 (de) Wirkstoffpflaster
EP0617972B1 (de) Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)-acrylat-Mischung
DE69417989T2 (de) Medizinischer Klebestreifen
EP1191927B1 (de) Mikroreservoirsystem auf basis von polysiloxanen und ambiphilen lösemitteln
EP1372619B1 (de) Verfahren zur herstellung eines hochflexiblen transdermalen therapeutischen systems mit nikotin als wirkstoff
EP2111857A1 (de) Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon
WO2002045699A2 (de) Transdermales therapeutisches system mit dem wirkstoff oxybutynin
EP2785334B1 (de) Transdermales therapeutisches system zur verabreichung von fentanyl oder einem analogstoff davon
DE19958554C2 (de) Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung
EP1087759B1 (de) Verfahren zur herstellung eines aus einzelnen schichten bestehenden laminats
DE4429791C2 (de) Medizinischer Haftkleber auf Basis von Polyacrylaten und dessen Verwendung
WO2006094681A1 (de) Faserfreies transdermales therapeutisches system und verfahren zu seiner herstellung
DE102006054733A1 (de) Transdermales therapeutisches Systems mit hoher Wirkstoffausnutzungsrate und Dosiergenauigkeit
EP0966273B1 (de) Transdermales oder topisches pflastersystem mit polyacrylatmatrix mit verbesserten physikalischen eigenschaften
EP1305378B1 (de) Medizinischer haftkleber mit einer zweiphasigen klebermatrix aus polyacrylaten und polyaminsalzen
DE3911699C2 (de) Pharmazeutische Zubereitung mit einem perkutan absorbierbaren Arzneimittel
EP3119444B1 (de) Überpflaster mit verbesserter verträglichkeit und einer langen haftungsdauer und verfahren zu seiner herstellung
DE19705138A1 (de) Dehnbares transdermales therapeutisches System
DE69419973T2 (de) Klebeband für medizinische Zwecke und Verfahren zu dessen Herstellung
DE102021128912A1 (de) Okklusives pflaster mit flexibler backing
EP3400965A1 (de) Ölige pflanzenextrakte enthaltende elemente und pflaster, die derartige wirkstoffhaltige elemente enthalten
DE4438989C2 (de) Scopolaminpflaster
WO2004069231A1 (de) Transdermales therapeutisches system mit verbessertem hautklebeverhalten
DD279818A1 (de) Verfahren zur herstellung eines medizinischen pflasters

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN CZ HU IL IN JP KR MX NZ PL RU TR US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2000958444

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020017005127

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 518037

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09830300

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020017005127

Country of ref document: KR

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN CZ HU IL IN JP KR MX NZ PL RU TR US ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 2000958444

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1020017005127

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2000958444

Country of ref document: EP